We advised the underwriters on the IPO and Nasdaq listing

Davis Polk advised the representatives of the several underwriters in connection with the $242.7 million initial public offering of 12,132,500 shares of Class A common stock of Century Therapeutics, Inc., which included 1,582,500 shares from the full exercise of the underwriters’ option to purchase additional shares. Century is traded on the Nasdaq Global Select Market under the trading symbol “IPSC.”

Century is a biotechnology company utilizing a comprehensive cell therapy platform to develop transformative allogeneic cell therapies with the potential to create products for the treatment of both solid tumor and hematological malignancies.

The Davis Polk capital markets team included partners Richard D. Truesdell Jr. and Roshni Banker Cariello and associates Arisa Akashi and Aaron Shubert. The intellectual property and technology transactions team included partner David R. Bauer and associates Christopher C. Woller and Brette L. Trost. The tax team included counsel Kiara L. Rankin and associate Dov Sussman. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York office.

Copy link to share post